Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
grade F 5.935 12.19% 0.65
ADVM closed up 2.32 percent on Friday, October 11, 2019, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ADVM trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 12.19%
Pocket Pivot Bullish Swing Setup 12.19%
Narrow Range Bar Range Contraction 12.19%
NR7 Range Contraction 12.19%
Oversold Stochastic Weakness 12.19%
Narrow Range Bar Range Contraction 14.80%
Doji - Bullish? Reversal 14.80%
Stochastic Reached Oversold Weakness 14.80%
Oversold Stochastic Weakness 14.80%
Narrow Range Bar Range Contraction 6.17%

Older signals for ADVM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Disease Gene Therapy Macular Degeneration Wet Age Related Macular Degeneration Gene Therapy Products Adverum Biotechnologies Gene Therapy Of The Human Retina Rare Genetic Disease Retinoschisis
Is ADVM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.3834
52 Week Low 2.62
Average Volume 2,162,896
200-Day Moving Average 7.7377
50-Day Moving Average 8.9772
20-Day Moving Average 5.653
10-Day Moving Average 5.4245
Average True Range 0.613
ADX 36.47
+DI 15.4129
-DI 32.929
Chandelier Exit (Long, 3 ATRs ) 7.921
Chandelier Exit (Short, 3 ATRs ) 6.799
Upper Bollinger Band 6.4323
Lower Bollinger Band 4.8737
Percent B (%b) 0.27
BandWidth 27.571201
MACD Line -1.0908
MACD Signal Line -1.2687
MACD Histogram 0.1779
Fundamentals Value
Market Cap 228.99 Million
Num Shares 43.3 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -3.48
Price-to-Sales 75.42
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.65
Resistance 3 (R3) 5.65 5.53 5.59
Resistance 2 (R2) 5.53 5.44 5.53 5.57
Resistance 1 (R1) 5.41 5.38 5.47 5.41 5.55
Pivot Point 5.29 5.29 5.32 5.29 5.29
Support 1 (S1) 5.17 5.20 5.23 5.17 5.03
Support 2 (S2) 5.05 5.14 5.05 5.01
Support 3 (S3) 4.93 5.05 4.99
Support 4 (S4) 4.93